

ROBO Global

13:25 27 Mar 2019

BioTelemetry's strength in cardiac monitoring puts it in the fast lane to growth, says ROBO Global

BioTelemetry Inc (NASDAQ:BEAT), a pioneer in the wireless medical technology space, is on the fast track to growth because of its strength in the mobile cardiac monitoring market, according to a report by ROBO Global.

Pennsylvania-based BioTelemetry's flagship product, the Mobile Cardiac Outpatient Telemetry (MCOT) system, gives cardiologists the ability to monitor their patients through the wearable technology they are using which shares data with their doctors through MCT transmitters.

"With the cardiac monitoring market poised to grow to \$32 billion by 2022 at a CAGR of 8%, Biotelemetry's strength in this area bodes well for its future," wrote ROBO Global senior research analyst Lisa Chai in a report. ROBO Global created the ROBO Global Robotics & Automation Index, the world's first benchmark index to track companies that focus on robotics, automation and artificial intelligence.

READ: BioTelemetry tops 3Q estimates as patient volume growth climbs higher, raises outlook

To date, Biotelemetry's MCOT devices have been used to monitor more than one million people per year and process over four billion heartbeats every day.

Before wearable devices like MCOT, monitoring and diagnosing heart disorders typically required hospital stays.

BioTelemetry is a ROBO Global index member and has delivered a total return of more than 443% to investors in the past three years.

Chai wrote that BioTelemetry's newest system incorporates "unparalleled arrhythmia detection capability" into a product that can be configured as an ultralight wearable patch, or used with more traditional lead wires when patients prefer not to wear a patch.

The analyst noted that competition is brewing in the space, but BioTelemetry is doing everything to stay ahead of competition.

READ: ROBO Global captures the high-octane growth of robotics and artificial intelligence
Medtronic PLC (NYSE:MDT), for example, recently released its implantable cardiac monitoring system.

According to Chai, iRhythm Technologies Inc (NASDAQ:IRTC) is the second-biggest player in the space, and offers a wearable biosensor called the Zio patch. Similarly, General Electric Company's (NYSE:GE) subsidiary GE Healthcare's MobileLink is a wireless, integrated ECG communication solution that captures, transmits and analyzes ECG information.

"To safeguard its market leadership, BioTelemetry holds 65 US patents and 134 international patents, and it currently has 56 active patent applications," wrote Chai.

Price: 38.77

Market Cap: \$2.16 billion

1 Year Share Price Graph



October 2018 April 2019 October 2019

Share Information

Code: ROBO

Listing: NYSE

52 week High Low
42.09 30.98

Sector: Tech

Website: www.roboglobal.com

Company Synopsis:

ROBO Global is an index, advisory, and research company focused 100% on helping investors capture the unique opportunities of fast-growing robotics, automation, and artificial intelligence (RAAI) companies around the world.

action@proactiveinvestors.com

To strengthen its competitive position, in July 2017 Biotelemetry acquired a heavy hitter in the space called LifeWatch.

It has also participated in a study which combines the iPhone, Apple Watch, and BioTelemetry's ePatch to screen for heart rhythm abnormalities in the general population.

"Its gross margin is impressive at 63%, with additional room to expand. These numbers have bolstered investor confidence in the company's ability to execute in every area—including research, product development, and sales," wrote Chai.

The ROBO Global Robotics & Automation Index ETF (NYSEARCA:ROBO) was down a little at \$38.16 in midday trade Wednesday.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ROBO Global named herein, including the promotion by the Company of ROBO Global in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).